A headline profit built on a mark-to-market

Centrus Energy reported third-quarter 2026 revenue of $55.5 million, down 26% year over year on lower delivery volumes. The GAAP bottom line showed diluted earnings of $1.41 per share — but $46.4 million of that came from a non-cash gain on the falling value of a warrant liability, an accounting revaluation rather than cash earned from selling fuel.

Strip that out and Centrus posted an adjusted net loss of roughly $9.4 million, or $0.46 per share. The gross line deteriorated too: a gross loss of $10.6 million, compared with a $4.3 million gross loss a year earlier.

Headline GAAP profit was $1.41 per share, but after excluding a non-cash warrant gain, Centrus posted an adjusted net loss of about $9.4 million, or $0.46 per share.

The balance sheet is the real story

Centrus ended the quarter with $2.2 billion in cash against $1.8 billion in debt, a buffer built on roughly $500 million raised through stock and pre-funded warrants with exercise prices reported around $227 to $363 per share. Management says full exercise of the warrants could eventually bring in about $2 billion more — but only if the stock more than triples from current levels.

That runway matters because the business is capital-hungry. Trailing free cash flow burn was $295 million, and management's near-term target is $350 million to $500 million of capital spending this year alone as it scales enrichment.

Backlog: $7 billion, but half is contingent

The commercial case rests on a $7 billion backlog of customer commitments running to 2040. About $5.4 billion of that is contingent orders for low-enriched uranium and HALEU — real interest, but not yet firm revenue.

What the market is pricing

Shares hit a fresh 52-week low of $84.86 before rebounding 17.5% to $104.60 after Roth Capital upgraded the stock to Buy with a $115 price target. Even after that bounce, Centrus remains down roughly 80% from an October 2025 peak above $450, below key moving averages, with $107 and $115 cited as reversal confirmation levels.

For HALEU watchers, the takeaway is that Centrus's strategic position — first mover on HALEU and the only U.S.-owned company enriching uranium for the commercial market — is intact. The financial proof of the HALEU era, however, is still ahead rather than in this quarter's print.

This article was assisted by AI analysis. Please refer to the original source for official information.